MX2023010370A - Vacuna del metapneumovirus humano. - Google Patents
Vacuna del metapneumovirus humano.Info
- Publication number
- MX2023010370A MX2023010370A MX2023010370A MX2023010370A MX2023010370A MX 2023010370 A MX2023010370 A MX 2023010370A MX 2023010370 A MX2023010370 A MX 2023010370A MX 2023010370 A MX2023010370 A MX 2023010370A MX 2023010370 A MX2023010370 A MX 2023010370A
- Authority
- MX
- Mexico
- Prior art keywords
- virus vaccine
- metapneumo virus
- human metapneumo
- vaccine composition
- respiratory system
- Prior art date
Links
- 241000342334 Human metapneumovirus Species 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 210000002345 respiratory system Anatomy 0.000 abstract 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 1
- 206010066226 Metapneumovirus infection Diseases 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
- C12N2710/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21167609 | 2021-04-09 | ||
| PCT/EP2022/059492 WO2022214678A2 (en) | 2021-04-09 | 2022-04-08 | Human metapneumo virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010370A true MX2023010370A (es) | 2023-09-12 |
Family
ID=75441775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010370A MX2023010370A (es) | 2021-04-09 | 2022-04-08 | Vacuna del metapneumovirus humano. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240181034A1 (enExample) |
| EP (2) | EP4319804A2 (enExample) |
| JP (1) | JP2024522385A (enExample) |
| KR (1) | KR20230167017A (enExample) |
| CN (1) | CN117279659A (enExample) |
| AU (1) | AU2022255923A1 (enExample) |
| BR (1) | BR112023017274A2 (enExample) |
| CA (1) | CA3210412A1 (enExample) |
| MX (1) | MX2023010370A (enExample) |
| WO (2) | WO2022214678A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220010478A (ko) | 2019-05-20 | 2022-01-25 | 발네바 에스이 | 기도 감염의 치료 또는 예방용 서브유닛 백신 |
| CN120548194A (zh) | 2023-01-18 | 2025-08-26 | 辉瑞公司 | 针对呼吸道疾病的疫苗 |
| WO2025119162A1 (zh) * | 2023-12-04 | 2025-06-12 | 深圳深信生物科技有限公司 | 偏肺病毒(mpv)疫苗 |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| CN119971017B (zh) * | 2025-04-16 | 2025-08-05 | 北京华诺泰生物医药科技有限公司 | 一种hmpv疫苗组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5547871A (en) | 1993-01-25 | 1996-08-20 | American Cyanamid Company | Heterologous signal sequences for secretion of insect controlling proteins |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| AT408721B (de) | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
| AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
| AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
| EP1390494A2 (en) | 2001-05-21 | 2004-02-25 | Intercell AG | Method for stabilising of nucleic acids |
| AU2004224746B2 (en) | 2003-03-24 | 2009-04-23 | Valneva Austria Gmbh | Improved vaccines |
| EP4400115A3 (en) | 2011-12-06 | 2024-10-23 | Valneva Austria GmbH | Aluminium compounds for use in therapeutics and vaccines |
| US10420834B2 (en) | 2014-12-24 | 2019-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant metapneumovirus F proteins and their use |
| WO2019092002A1 (en) * | 2017-11-07 | 2019-05-16 | Valneva Se | Pharmaceutical compositions for treatment or prevention of viral infections |
| KR20220010478A (ko) * | 2019-05-20 | 2022-01-25 | 발네바 에스이 | 기도 감염의 치료 또는 예방용 서브유닛 백신 |
-
2022
- 2022-04-08 KR KR1020237028871A patent/KR20230167017A/ko active Pending
- 2022-04-08 AU AU2022255923A patent/AU2022255923A1/en not_active Abandoned
- 2022-04-08 EP EP22719593.0A patent/EP4319804A2/en active Pending
- 2022-04-08 US US18/285,416 patent/US20240181034A1/en active Pending
- 2022-04-08 CA CA3210412A patent/CA3210412A1/en active Pending
- 2022-04-08 BR BR112023017274A patent/BR112023017274A2/pt unknown
- 2022-04-08 JP JP2023554016A patent/JP2024522385A/ja active Pending
- 2022-04-08 US US18/285,417 patent/US20240358812A1/en active Pending
- 2022-04-08 CN CN202280015950.4A patent/CN117279659A/zh active Pending
- 2022-04-08 EP EP22716270.8A patent/EP4319802A2/en active Pending
- 2022-04-08 WO PCT/EP2022/059492 patent/WO2022214678A2/en not_active Ceased
- 2022-04-08 WO PCT/EP2022/059502 patent/WO2022214685A2/en not_active Ceased
- 2022-04-08 MX MX2023010370A patent/MX2023010370A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117279659A (zh) | 2023-12-22 |
| EP4319804A2 (en) | 2024-02-14 |
| WO2022214685A2 (en) | 2022-10-13 |
| US20240358812A1 (en) | 2024-10-31 |
| WO2022214685A3 (en) | 2023-03-09 |
| US20240181034A1 (en) | 2024-06-06 |
| WO2022214678A2 (en) | 2022-10-13 |
| KR20230167017A (ko) | 2023-12-07 |
| JP2024522385A (ja) | 2024-06-19 |
| EP4319802A2 (en) | 2024-02-14 |
| AU2022255923A1 (en) | 2023-08-31 |
| WO2022214678A3 (en) | 2023-05-04 |
| CA3210412A1 (en) | 2022-10-13 |
| BR112023017274A2 (pt) | 2023-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022214678A3 (en) | Human metapneumo virus vaccine | |
| PH12021552736A1 (en) | A subunit vaccine for treatment or prevention of a respiratory tract infection | |
| CR20210306A (es) | Proteínas f de prefusión del vrs estabilizadas | |
| PH12019502201A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| PH12018550150B1 (en) | Elimination of hepatitis b virus with antiviral agents | |
| PH12019502577A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| PH12019502095A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| MY195194A (en) | Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors | |
| PH12019502559A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| PH12018501962A1 (en) | Stablizied soluble pre-fusion rsv f proteins | |
| PH12018502332A1 (en) | Stabilized pre-fusion rsv f proteins | |
| MX2022009871A (es) | Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih). | |
| MY194294A (en) | Novel viral replication inhibitors | |
| JOP20150335B1 (ar) | مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك | |
| MX2021010145A (es) | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. | |
| MX2023009447A (es) | Anticuerpos que se unen a metapneumovirus, proteínas antigénicas de metapneumovirus, y usos de los mismos. | |
| ZA201906327B (en) | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | |
| PH12016502039A1 (en) | Potent and selective inhibitors of hepatitis c virus | |
| PH12015502128A1 (en) | Novel dosing regimens of celgosivir for the treatment of dengue | |
| CR20220453A (es) | Composiciones de palmitato de vitamina a, procesos para su preparación, usos y métodos que las componen | |
| MX2021013594A (es) | Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. | |
| WO2022065971A3 (ko) | 지구자 추출물을 포함하는 코로나바이러스 감염 예방 또는 치료용 조성물 | |
| BR112018009032A2 (pt) | vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração | |
| EA201992295A1 (ru) | Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге |